What's Happening?
LEO Pharma announced that the FDA has accepted its supplemental New Drug Application for ANZUPGO® (delgocitinib) cream, intended for treating chronic hand eczema in children aged 12-17. This cream, a non-steroidal pan-Janus kinase inhibitor, is already
approved for adults with moderate to severe chronic hand eczema. The application is supported by positive data from the DELTA TEEN trial, which demonstrated the cream's efficacy and safety in pediatric patients.
Why It's Important?
The FDA's acceptance of this application marks a significant step towards addressing the unmet medical needs of pediatric patients with chronic hand eczema. If approved, ANZUPGO would be the first treatment specifically indicated for this age group, offering a new option for managing a condition that can significantly impact quality of life. This development underscores the importance of expanding treatment options for underserved populations and could lead to further advancements in pediatric dermatology.
What's Next?
The FDA will review the application, and if approved, ANZUPGO could become available for pediatric use, potentially improving care for children with chronic hand eczema. The decision could also influence future research and development in pediatric dermatology, encouraging more targeted treatments for young patients. Stakeholders, including healthcare providers and patient advocacy groups, will likely monitor the FDA's decision closely.
